Scientists find a molecular switch for nerve repair — and why diabetes turns it off
Chronic nerve pain feels like a death sentence. The burning, the shooting, the tingling that won't stop — for the 25 million Americans with diabetic neuropathy, and for chemotherapy patients whose nerves never fully recovered from the toxins that saved their lives, this is Tuesday. Drugs help. Mostly they dull the signal without fixing the wire.
A study published in Nature in January 2026 — and repackaged this week by ScienceDaily — argues that some of this pain may not be inevitable at all. The body has a built-in mechanism for repairing damaged nerves. Diabetes breaks that mechanism. And the break has a specific address: a scaffold protein called myosin 10, or MYO10.
The discovery starts with a curious observation in mouse tissue. When satellite glial cells — a type of supporting cell that clusters around the sensory neurons in your dorsal root ganglia, the cluster of nerve roots at the base of the spine — were placed near damaged neurons, something striking happened. The glial cells extended thin membranous tunnels called tunneling nanotubes, and shipped spare mitochondria through them directly into the injured neurons. The neurons, running low on energy, perked up. According to the NIH, mitochondria from healthy human donors decreased pain sensitivity in mice with both diabetic neuropathy and chemotherapy-induced nerve damage. Mitochondria from human donors with diabetes did not.
MYO10 is what these tunneling nanotubes are built from. It is the structural protein that gives the nanotube its shape — the scaffold that holds the bridge together while mitochondria travel across it. The researchers, led by Xu et al. and cited by The Scientist in their coverage of the work, found that MYO10 is highly expressed in human satellite glial cells. But in tissue taken from diabetic patients, MYO10 expression in those same cells was visibly reduced. Fewer scaffolding proteins meant fewer tunneling nanotubes, which meant fewer mitochondria getting through.
The causal chain is what makes the result interesting, not just the correlation. When the researchers blocked mitochondrial transfer in healthy mice — essentially cutting the supply line even in animals without diabetes — the mice developed neuropathic pain symptoms even though nothing was directly wrong with their nerves. The pain came from the interruption of repair, not from an external injury. Conversely, increasing mitochondrial transfer in mice with existing nerve damage reduced pain-related behaviors by as much as 50 percent, according to ScienceDaily. In some cases, relief lasted up to 48 hours after a single treatment.
The transfer rate is itself a revealing number. In co-culture experiments, 83.3 percent of sensory neurons received mitochondria from satellite glial cells, even though only 31.3 percent of neurons had visible tunneling nanotubes attached. This suggests the nanotubes are fragile and temporary, or that some mitochondrial transfer happens through other routes. Either way, the majority of neurons in a healthy system get replenished.
Why diabetes specifically disrupts MYO10 expression remains an open question the paper does not fully answer. The study was done in mice and in human tissue samples, which is a meaningful step up from cell culture alone, but the leap to human treatment is not small. Peripheral neuropathy in humans develops over years of metabolic stress. Mouse models compress that timeline dramatically, and what looks like a repair mechanism in a six-week-old diabetic mouse may not translate directly to a 60-year-old human with a decade of accumulated damage.
The therapeutic implications are multiple and somewhat tangled. One path is to identify drugs that boost MYO10 expression, essentially telling satellite glial cells to build more bridges. Another is cell therapy: transplanting healthy satellite glial cells, or mitochondria alone, directly into the dorsal root ganglion. Both are early-stage ideas. The paper demonstrates the mechanism; the drug development would take years.
What the paper does accomplish is a precise reclassification of where the problem lives. Neuropathy is commonly framed as a consequence of high blood sugar damaging nerves over time. This work suggests that some fraction of diabetic nerve damage is not damage per se but a failure of maintenance — the repair supply chain running below the threshold needed to keep up with wear. That is a different disease model, and it suggests different intervention points.
The broader context is a quiet shift in how cell biologists think about mitochondria. For decades, mitochondria were cellular batteries: you burned them for energy and that was the job. The discovery of mitochondrial transfer — that cells can ship intact mitochondria to other cells like a repair crew moving into a damaged building — adds a second function: cellular logistics and repair. This is not a brand new observation; the tunneling nanotube phenomenon has been described in other cell types. But the specific demonstration in sensory neurons, tied to a concrete molecular scaffold, gives the mechanism a sharpness that earlier, more scattered observations lacked.
Whether that sharpness translates into a therapy is a question for a different kind of study. For the 25 million Americans with diabetic neuropathy, and the smaller but significant group of cancer survivors with chronic chemotherapy-related nerve pain, the paper offers something that existing drugs do not: a mechanistic explanation for why the pain persists, and a molecular switch that, if the science holds, could theoretically be flipped back on.